Skip to main content

elzonris

Generic: tagraxofusp-erzs

elzonris: sourced relationships with 1 company · 1 FDA decision.

elzonris evidence translation

What we can confirm

What it means

Source-backed records connect elzonris to STML; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could elzonris → STML affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (1)
CompanyDated record stage
STEMLINE THERAPEUTICS INC (STML)
developer · Reported 2019-03-15 · Current development: unknownSource
blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE ELZONRIS is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older. ELZONRIS is a CD123-directed cytotoxin indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older ( 1 )(STML)FDA ↗
BLA761116Type 1 - New Molecular EntityOrphan DrugPriorityOtherSolution

Frequently asked questions

Which companies have sourced relationships with elzonris?

elzonris has dated SEC/FDA relationship records for STEMLINE THERAPEUTICS INC.

What is elzonris's latest FDA decision?

The most recent tracked FDA decision for elzonris is Approval for 1 INDICATIONS AND USAGE ELZONRIS is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older. ELZONRIS is a CD123-directed cytotoxin indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older ( 1 ), dated December 21, 2018.